

REMARKS


Claims 26, and 28-42 are presented in this application. By way of this amendment, claims 26, 28, and 40 have been amended, claims 29-39 and 41 have been canceled, and claims 43-52 have been added. No new matter has been added.

Support for the amendments may be found generally in the originally-filed specification and claims. More specifically, support for amendments to the composition claims may be found on pages 19 and 20 of the specification. Support for amendments to the method of treatment claims may be found in the original claim set. Support for the added process claim may be found in example 10 of the specification.

It is respectfully requested that the instant application, with the claims as submitted in this amendment, be examined. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,



J. Scott Young
Attorney for Applicant
Registration No. 45,582

Date: March 13 2008
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8160
Facsimile: 919-483-7988